Holen Sie sich die Stockscreener-App
5.14
4.64%
-0.25
Handel nachbörslich:
5.16
0.02
+0.39%
Schlusskurs vom Vortag:
$5.39
Offen:
$5.495
24-Stunden-Volumen:
4.68M
Relative Volume:
2.98
Marktkapitalisierung:
$457.46M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+22.38%
1M Leistung:
+42.78%
6M Leistung:
+54.35%
1J Leistung:
+0.00%
1-Tages-Spanne:
$5.075
$5.65
1-Wochen-Bereich:
$4.16
$5.75
52-Wochen-Spanne:
$1.42
$5.75
Atyr Pharma Inc Stock (ATYR) Company Profile
Firmenname
Atyr Pharma Inc
Sektor
Branche
Telefon
(858) 731-8389
Adresse
10240 SORRENTO VALLEY ROAD, SAN DIEGO
Vergleichen Sie ATYR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ATYR
Atyr Pharma Inc
|
5.14 | 373.82M | 0 | 0 | 0 | 0.00 |
|
ONC
Beone Medicines Ltd Adr
|
258.27 | 26.01B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.85 | 114.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.3499 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
83.98 | 6.29B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
484.93 | 63.90B | 14.09B | 4.50B | 2.96B | 39.28 |
Atyr Pharma Inc Stock (ATYR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-18 | Eingeleitet | Leerink Partners | Outperform |
| 2025-01-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-10-04 | Eingeleitet | Wells Fargo | Overweight |
| 2024-09-05 | Eingeleitet | Jefferies | Buy |
| 2023-07-05 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-10-12 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-09-21 | Eingeleitet | Piper Sandler | Overweight |
| 2021-05-10 | Eingeleitet | Laidlaw | Buy |
| 2020-08-17 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-03-04 | Eingeleitet | ROTH Capital | Buy |
| 2020-03-02 | Eingeleitet | Oppenheimer | Outperform |
| 2018-02-14 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2017-09-07 | Eingeleitet | Piper Jaffray | Overweight |
| 2016-12-13 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2015-12-16 | Eingeleitet | Citigroup | Neutral |
| 2015-06-01 | Eingeleitet | Citigroup | Buy |
| 2015-06-01 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Atyr Pharma Inc Aktie (ATYR) Neueste Nachrichten
aTyr Pharma Announces Findings from Interim Analysis of - GlobeNewswire
ATYR Stock Update: HC Wainwright Reiterates 'Buy' Rating with $3 - GuruFocus
aTyr Pharma reports positive interim results for SSc-ILD treatment - Investing.com
aTyr Pharma (ATYR) Reports Promising Interim Results for Efzofitimod | ATYR Stock News - GuruFocus
aTyr Pharma reports positive interim results for SSc-ILD treatment By Investing.com - Investing.com Nigeria
aTyr Pharma Announces Findings from Interim Analysis of Ongoing Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD) - Yahoo Finance
Millennium Management LLC Takes $1.33 Million Position in Atyr PHARMA INC (NASDAQ:ATYR) - Defense World
aTyr Pharma (ATYR) Scheduled for Key Presentation in New York | - GuruFocus
aTyr Pharma (ATYR) Scheduled for Key Presentation in New York | ATYR Stock News - GuruFocus
aTyr Pharma stock soars to 52-week high of $4.66 By Investing.com - Investing.com Nigeria
182,625 Shares in Atyr PHARMA INC (NASDAQ:ATYR) Bought by Northern Trust Corp - Defense World
Atyr PHARMA INC (NASDAQ:ATYR) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
High Growth Tech Stocks in the US to Watch This May 2025 - Yahoo Finance
Group One Trading LLC Takes $26,000 Position in Atyr PHARMA INC (NASDAQ:ATYR) - Defense World
Jane Street Group LLC Invests $720,000 in Atyr PHARMA INC (NASDAQ:ATYR) - Defense World
aTyr Pharma’s SWOT analysis: biotech firm’s stock poised for potential breakthrough - Investing.com India
aTyr Pharma’s SWOT analysis: biotech firm’s stock poised for potential breakthrough By Investing.com - Investing.com South Africa
aTyr Pharma, Inc. (ATYR): Analysts See 485% Upside Potential - Insider Monkey
aTyr Pharma to Present at Upcoming Investor Conferences - GlobeNewswire
aTyr Pharma Announces Triple Conference Schedule: RBC, Jefferies, and Piper Sandler Healthcare Events Coming Up - Stock Titan
13 Best Multibagger Stocks to Invest in Now - Insider Monkey
Atyr PHARMA (NASDAQ:ATYR) Receives Buy Rating from HC Wainwright - Defense World
aTyr Pharma (ATYR) Highlights Efzofitimod Research at ATS 2025 | ATYR Stock News - GuruFocus
aTyr Pharma (ATYR) Highlights Efzofitimod Research at ATS 2025 | - GuruFocus
aTyr Pharma (ATYR) Receives Steady 'Buy' Rating from HC Wainwright | ATYR Stock News - GuruFocus
Such Is The Power Of Atyr Pharma Inc (NASDAQ: ATYR) - Stocksregister
aTyr Pharma Presents Three Posters on Efzofitimod at the - GlobeNewswire
Breakthrough Phase 3 Trial Reveals 158,900 Patients Could Benefit from New Sarcoidosis Treatment - Stock Titan
Balyasny Asset Management L.P. Buys Shares of 44,310 Atyr PHARMA INC (NASDAQ:ATYR) - Defense World
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rul - GuruFocus
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
ATyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com
aTyr Pharma Awards 36,200 Shares in Stock Options Under Nasdaq Rule 5635Key Details Revealed - Stock Titan
Dimensional Fund Advisors LP Makes New $881,000 Investment in Atyr PHARMA INC (NASDAQ:ATYR) - Defense World
Atyr begins IND-enabling studies with candidate for pulmonary fibrosis - BioWorld MedTech
10,694 Shares in Atyr PHARMA INC (NASDAQ:ATYR) Acquired by Raymond James Financial Inc. - Defense World
aTyr Pharma advances new fibrosis treatment candidate By Investing.com - Investing.com South Africa
ATyr Pharma Plans Investigational New Drug Filing for ATYR0101 in Pulmonary Fibrosis - marketscreener.com
aTyr Pharma (ATYR) to Present ATYR0101 at 2025 ATS Summit | ATYR Stock News - GuruFocus
aTyr Pharma advances new fibrosis treatment candidate - Investing.com
aTyr Pharma Advances ATYR0101 to IND Candidate Stage for Pulmonary Fibrosis - GlobeNewswire
Revolutionary Fibrosis-Reversing Drug ATYR0101 Shows Promise in Targeting Deadly Lung Disease - Stock Titan
Schonfeld Strategic Advisors LLC Takes Position in Atyr PHARMA INC (NASDAQ:ATYR) - Defense World
Q3 Earnings Forecast for Atyr PHARMA Issued By HC Wainwright - Defense World
Leerink Partnrs Estimates Atyr PHARMA Q2 Earnings - Defense World
Is aTyr Pharma, Inc. (ATYR) the Low Risk High Reward Stock Set to Triple by 2030? - Insider Monkey
Barclays PLC Acquires New Position in Atyr PHARMA INC (NASDAQ:ATYR) - Defense World
10 Low Risk High Reward Stocks Set to Triple by 2030 - Insider Monkey
Pulmonary Sarcoidosis Market to Reach New Heights in Growth - openPR.com
Atyr Pharma: Q1 Earnings Snapshot - New Haven Register
Finanzdaten der Atyr Pharma Inc-Aktie (ATYR)
Es liegen keine Finanzdaten für Atyr Pharma Inc (ATYR) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.00%
0.54%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):